Evidence map›Paper›PMID 40607222›Full record

Trial reportFrontiers in endocrinology2025

Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.

Cheng-Lan Xu, Xiao-Cen Kong, Xiao-Mei Liu, Xiao-Hua Xu, Bing-Li Liu, Jian-Hua Ma

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05990374. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05990374 naunknown status

Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

Ran2023Enrolled100Registered outcomes2Posted comparisons0ConditionsDiabetesArmsDuragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cheng-Lan XuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiao-Cen KongDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiao-Mei LiuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiao-Hua XuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Bing-Li LiuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jian-Hua MaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Investigate effects of Ebenatide, a novel glucagon-like peptide-1 analogue, on glycemic control and body composition in type 2 diabetes mellitus (T2DM). Methods: This randomized, prospective, interventional study enrolled 78 subjects (76 finished). Subjects were randomized to either the Ebenatide group (52 subjects, Ebenatide for 52 weeks) or the placebo group (24 subjects, placebo for 24 weeks followed by Ebenatide for 28 weeks) according to a 2:1 allocation ratio. Assessments included continuous glucose monitoring and body composition analysis. Results: The Ebenatide group showed significantly lower in hemoglobin A1c (HbA1c), mean blood glucose (MBG), time above range (TAR) and standard deviation (SD), along with improvement of time in range (TIR) at Week 24 and Week 52 compared to baseline ( Conclusion: Ebenatide treatment for 24 weeks significantly improved HbA1c, TIR, TyG, weight and WHtR in T2DM subjects, with these benefits sustained for at least 52 weeks. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT05990374.

Indexed as

Adipose TissueBlood GlucoseDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Hypoglycemic AgentsAdultAgedBody CompositionFemaleGlycated HemoglobinGlycemic ControlHumansMaleMiddle AgedProspective StudiesBlood GlucoseGlucagon-Like Peptide 1Glycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsbody fatcontinuous glucose monitoringEbenatideGLP-1type 2 diabetes mellitus

Identifiers

PMID40607222
PMCPMC12213378

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.